LOADING
Comparing Eli Lilly and Company (LLY) and Merck & Company (MRK), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | LLY | MRK |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $905.8B | $280.2B |
| P/E Ratio | 35.2 | 32.0 |
| Forward P/E | 26.3 | 22.0 |
| PEG Ratio | 1.28 | 5.18 |
| EPS | $28.85 | $3.55 |
| Revenue Growth (YoY) | 55.5% | 4.9% |
| Profit Margin | 35.0% | 13.6% |
| Return on Equity | 107.5% | 18.9% |
| Dividend Yield | 0.63% | 2.92% |
| Beta | 0.48 | 0.20 |
| 52-Week High | $1,132.06 | $124.22 |
| 52-Week Low | $620.46 | $71.76 |
| Volume | -- | -- |
Eli Lilly and Company is the larger company by market capitalization. Merck & Company trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. Eli Lilly and Company has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.